Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Allergy Therapeutics PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Total Equity
ÂŁ26.5m
CAGR 3-Years
-23%
CAGR 5-Years
-10%
CAGR 10-Years
2%
GlaxoSmithKline PLC
LSE:GSK
Total Equity
ÂŁ14.4B
CAGR 3-Years
-2%
CAGR 5-Years
32%
CAGR 10-Years
9%
AstraZeneca PLC
LSE:AZN
Total Equity
$39.5B
CAGR 3-Years
36%
CAGR 5-Years
24%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Equity
$130.5m
CAGR 3-Years
-8%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Equity
$2.3B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
7%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Equity
ÂŁ755.2m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Total Equity?
Total Equity
26.5m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Total Equity amounts to 26.5m GBP.

What is Allergy Therapeutics PLC's Total Equity growth rate?
Total Equity CAGR 10Y
2%

Over the last year, the Total Equity growth was -30%. The average annual Total Equity growth rates for Allergy Therapeutics PLC have been -23% over the past three years , -10% over the past five years , and 2% over the past ten years .

Back to Top